ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO085

Proton Pump Inhibitor Use and Risk of AKI: A Meta-Analysis of Observational Studies

Session Information

  • AKI Clinical: Predictors
    November 03, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational

Authors

  • Yang, Yi, Tongji hospital affiliated to Tongji medical college, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, China
  • Xu, Gang, Tongji Hospital, Tongji Medical College, Huazhong Univ of Science and Technology, WUHAN, China
  • Ge, Shuwang, Tongji Hospital, Huazhong University of Science and Technology, WUHAN, China
Background

Recent studies have suggested a potential increased risk of acute kidney injury (AKI) among proton pump inhibitor (PPI) users. However, the present results are conflicting. Thus, we performed a meta-analysis to investigate the association between PPI therapy and the risk of AKI.

Methods

EMBASE, PubMed, Web of Science and Cochrane Library databases (up to September 23, 2016) were systematically searched for any studies assessing the relation between PPI use and risk of AKI. Studies that reported relevant relative risks (RRs), odds ratios or hazard ratios were included. We calculated the pooled relative risks with 95% confidence intervals (CI) using a random effects model of the meta- analysis. Subgroup analysis was conducted to explore the source of heterogeneity.

Results

Seven observational studies (five cohort studies, two case-control studies) were identified and included, and a total of 513,696 cases of PPI use among 2,404,236 participants were included in the meta-analysis. The pooled adjusted RR of AKI in patients with PPIs use was 1.61 (95% CI, 1.16–2.22; I2=98.1%). Furthermore, higher risks of AKI were found in several subgroups of cohort studies, participant’s average age < 60 years, participants with and without baseline PPI excluded, sample size < 300,000, and number of adjustments ≥ 11. Subgroup analyses revealed that participants with or without baseline PPI excluded might be a source of heterogeneity.

Conclusion

PPI use could be a risk factor for AKI and should be administered carefully. Nevertheless some confounding factors might impact the outcomes. More well-designed prospective studies are needed to clarify the association.

Figure 2 association between proton-pump inhibitors use and risk of acute kidney injury

Funding

  • Government Support - Non-U.S.